Why to avoid dual primary endpoints in cardiovascular trials
Year: 2025
Type: conference-paper
Abstract: Introduction: In an adequately designed randomised controlled trial for confirming the efficacy of a new drug in patients with chronic heart failure (CHF), mortality (all-cause or cardiovascular) should usually be the primary endpoint – either alone or as a part of a composite endpoint with outcomes [for full text, please go to the a.m. URL]
DOI: 10.3205/25gmds075
Authors: Thomas, Nele, Großhennig, Anika, Koch, Armin, Liu, Xiaofei
Institution: Medizinische Hochschule Hannover
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7103892299
FWCI:
Cites:
Cited by:
Related to: